Funds holding Vir Biotechnology Inc
ISIN US92764N1028 · United States
- Fund holders
- 231
- Of which ETFs
- 55 176 other funds
- Value held
- 404.3M $
- Share of capital
- 26.0 % of 169.2M shares on Jul 29, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| PROFUND VP SMALLCAP VALUE ProFunds | 1,677 | 15K $ | 0.08 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Hypatia Women CEO ETF Two Roads Shared Trust | 1,571 | 16K $ | 0.19 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Fidelity Flex Small Cap Focused Index Fund Fidelity Salem Street Trust | 1,496 | 15.3K $ | 0.10 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Nuveen Life Stock Index Fund TIAA-CREF Life Funds | 1,193 | 10.7K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF SPDR INDEX SHARES FUNDS | 1,124 | 10.1K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 1,070 | 9.6K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 1,052 | 10.7K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Ultra SmallCap600 ProShares Trust | 1,037 | 9.4K $ | 0.04 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Gotham Enhanced Return Fund FundVantage Trust | 935 | 8.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALLCAP GROWTH ProFunds | 922 | 8.3K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P SmallCap 600 ESG ETF SPDR SERIES TRUST | 866 | 7.8K $ | 0.11 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 774 | 6.9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 705 | 7.2K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 595 | 6.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 580 | 5.2K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Gotham Neutral Fund FundVantage Trust | 560 | 5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP VALUE PROFUND ProFunds | 456 | 4.7K $ | 0.08 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 454 | 4.1K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| THRIVENT MODERATELY CONSERVATIVE ALLOCATION FUND Thrivent Mutual Funds | 442 | 4.5K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 312 | 2.8K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP GROWTH PROFUND ProFunds | 250 | 2.6K $ | 0.06 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 236 | 2.1K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 209 | 1.9K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 170 | 1.7K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 125 | 1.1K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Total Equity Markets ETF American Century ETF Trust | 101 | 918.1 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 91 | 827.2 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 91 | 815.4 $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 27 | 245.4 $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 24 | 215 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) 1500 Momentum Tilt ETF SPDR SERIES TRUST | 9 | 80.6 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 1.13 % | as of Apr 30, 2026 ↗ |
| Disciplined U.S. Small Cap Equity Portfolio GLENMEDE FUND INC | 1.07 % | as of Apr 30, 2026 ↗ |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 1.07 % | as of Apr 30, 2026 ↗ |
| Global X Genomics & Biotechnology ETF GLOBAL X FUNDS | 0.70 % | as of Feb 28, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.67 % | as of Mar 31, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 0.66 % | as of Feb 28, 2026 ↗ |
| NVIT Small Cap Value Fund Nationwide Variable Insurance Trust | 0.53 % | as of Mar 31, 2026 ↗ |
| VANGUARD MARKET NEUTRAL FUND VANGUARD MONTGOMERY FUNDS | 0.52 % | as of Mar 31, 2026 ↗ |
| Invesco S&P SmallCap Health Care ETF Invesco Exchange-Traded Fund Trust II | 0.51 % | as of Feb 28, 2026 ↗ |
| NVIT Multi-Manager Small Company Fund Nationwide Variable Insurance Trust | 0.31 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 231 | +29 | 44,038,410 | +17.7 % |
| 2026Q1 | 202 | -11 | 37,427,585 | +0.7 % |
| 2025Q4 | 213 | +2 | 37,180,670 | -6.2 % |
| 2025Q3 | 211 | -8 | 39,644,756 | -3.4 % |
| 2025Q2 | 219 | +9 | 41,039,838 | +3.6 % |
| 2025Q1 | 210 | -6 | 39,625,260 | +7.3 % |
| 2024Q4 | 216 | -15 | 36,934,401 | +4.9 % |
| 2024Q3 | 231 | +11 | 35,218,741 | -4.9 % |
| 2024Q2 | 220 | -13 | 37,039,881 | -1.8 % |
| 2024Q1 | 233 | -18 | 37,728,111 | -3.2 % |
| 2023Q4 | 251 | 38,994,011 |
Institutional managers
242 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 17,998,329 | 161.3M $ | as of Mar 31, 2026 |
| ARCH Venture Management, LLC | 12,916,663 | 115.7M $ | as of Mar 31, 2026 |
| SB INVESTMENT ADVISERS (UK) LTD | 10,948,093 | 98.1M $ | as of Mar 31, 2026 |
| GSK plc | 8,550,954 | 76.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 7,141,094 | 64M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 3,250,227 | 29.1M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,854,205 | 25.6M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 2,744,714 | 24.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,657,843 | 23.8M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,579,678 | 23.1M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 2,098,476 | 18.8M $ | as of Mar 31, 2026 |
| FMR LLC | 2,071,848 | 18.6M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 2,002,000 | 17.9M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 1,952,234 | 17.5M $ | as of Mar 31, 2026 |
| Boxer Capital Management, LLC | 1,866,000 | 16.7M $ | as of Mar 31, 2026 |
| GordonMD Global Investments LP | 1,518,552 | 13.6M $ | as of Mar 31, 2026 |
| Sio Capital Management, LLC | 1,498,620 | 13.4M $ | as of Mar 31, 2026 |
| Pictet Asset Management Holding SA | 1,480,828 | 13.3M $ | as of Mar 31, 2026 |
| Hudson Bay Capital Management LP | 1,469,510 | 13.2M $ | as of Mar 31, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,442,336 | 12.9M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1,439,494 | 12.9M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 1,248,669 | 11.2M $ | as of Mar 31, 2026 |
| Clearstead Advisors, LLC | 1,216,400 | 10.9M $ | as of Mar 31, 2026 |
| Jones Hill Capital LP | 1,198,213 | 10.7M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,171,684 | 10.5M $ | as of Mar 31, 2026 |
Declared shareholders of Vir Biotechnology Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| SB Investment Advisers (UK) Limited and 2 others | 6.50 % | 10,948,093 | as of Mar 31, 2026 · SCHEDULE 13G |
| Vanguard Portfolio Management | 5.79 % | 9,257,235 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Vir Biotechnology Inc". https://titelia.com/en/stocks/vir-biotechnology-inc-US92764N1028